Corona vaccine: Moderna wants to apply for approval in Europe today

The US pharmaceutical company Moderna wants to apply for approval for its corona vaccine in the EU on Monday.

At the same time, an emergency license is to be applied for in the USA.

• The US pharmaceutical company

  Moderna

  has developed a

  vaccine

  against the

  coronavirus *

  .

• On Monday, the company wants to

  apply for

  approval

  in the

  EU

  .

• The

  Corona vaccine *

  According to Moderna has an

  efficiency of 94.1 percent

  .

New York - The US pharmaceutical company

wants to be the first company to

in the

.

The application for a conditional approval should be submitted to the European Medicines Agency EMA on Monday, the company said.

At the same time, an

for

to be

to the US

.

Corona vaccine: Moderna wants to apply for approval in Europe

With the application for approval at the EMA, a

also

getting closer

in

.

Last week, EU Commission chief

that

a framework contract for

had been concluded

with

.

Accordingly, 80 million cans are to be delivered initially, with the option of 80 million more units.

According to Moderna, the product could be

delivered

in the EU

, provided it receives approval.

We just announced the primary efficacy analysis in the Phase 3 COVE study for mRNA-1273, our COVID-19 vaccine candidate and that today, we plan to request an Emergency Use Authorization from the US FDA & conditional approval from the EMA.

Read more: https://t.co/90FbcVHdWN pic.twitter.com/36tpY0QeFl

- Moderna (@moderna_tx) November 30, 2020

A

so-called

already running at the EMA for

the

from 

, which is intended to accelerate the approval process.

Manufacturers can submit individual parts on the quality, safety and effectiveness of a preparation even before the complete application for approval.

Moderna corona vaccine: 94.1 percent effectiveness

The

has an

, the company said.

This emerges from the latest analysis of data from the

, in which 30,000 people in the 

participating.

Half of the participants receive the vaccine, the other half a placebo.

For full vaccination protection, two doses are necessary at intervals.

A total of

the disease

confirmed

among the test persons so far

.

11 of these cases were in the vaccine group and 185 in the placebo group.

This results in an

.

The new results roughly correspond to the preliminary data that

mid-November.

The company also announced that the total of

in the study

affected

.

The

of mRNA-1273 was similar across all age groups, according to Moderna.